News

GSK Pharma Q4 Results: Net profit at ₹260 crore; ₹42 dividend declaredThe board has recommended a final dividend of ₹42 per equity share on face value of ₹10 each for the year ended March 31, 2025, subject to approval of members at 100th Annual General Meeting.By CNBCTV18.com May 13, 2025, 4:44:08 PM IST (Published)2 Min ReadFor the quarter ended March 31, 2025, GlaxoSmithKline Pharmaceuticals Ltd. reported a revenue of ₹966 crore, a like-to-like growth of 6%. Profit for the quarter stood at ₹260 crore.

The company reported full year revenue of ₹3,723 crore, a growth of 9%. Profit increased by 32% to ₹915 crore and EBITDA margins increased by 500 basis points to 31.4%.

Bhushan Akshikar, Managing Director of GlaxoSmithKline Pharmaceuticals said, "Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult

vaccination ecosystem in the country.”

“We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,” he added.

The company said its on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer.

The board has recommended a final dividend of ₹42 per equity share on face value of ₹10 each for the year ended March 31, 2025, subject to approval of members at 100th Annual General Meeting.

Record date for the said dividend has been fixed as May 30, 2025.

Shares of GlaxoSmithKline Pharmaceuticals Ltd. ended 3.22% higher at ₹2,809. The stock has risen over 25% so far in 2025.Continue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!TagsearningsGSK Pharma